APOC1 anticorps (AA 35-48)
Aperçu rapide pour APOC1 anticorps (AA 35-48) (ABIN7144415)
Antigène
Voir toutes APOC1 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 35-48
-
Réactivité croisée
- Humain
-
Purification
- >95%, Protein G purified
-
Immunogène
- Recombinant Human Apolipoprotein C-I protein (35-48aa)
-
Isotype
- IgG
-
-
-
-
Indications d'application
- Recommended dilution: IHC:1:100-1:500,
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4 -
Agent conservateur
- ProClin
-
Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C,-80 °C
-
Stockage commentaire
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
-
- APOC1 (Apolipoprotein C-I (APOC1))
-
Autre désignation
- APOC1
-
Sujet
-
Background: Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10 % of the protein of the VLDL and 2 % of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.
Aliases: Apolipoprotein C-I (Apo-CI) (ApoC-I) (Apolipoprotein C1) [Cleaved into: Truncated apolipoprotein C-I], APOC1
-
UniProt
- P02654
-
Pathways
- Apoptose
Antigène
-